In addition, the amplification of Tregs with a low-dose IL-2 treatment has been shown to be well tolerated in different clinical pathological conditions51 and in AD murine models16, supporting possible immunotherapeutic prospective based on the modulation of Tregs in the AD. This evidence concerns the gene IL2 and Alzheimer disease.